Røsjø Egil, Myhr Kjell-Morten, Løken-Amsrud Kristin I, Bakke Søren J, Beiske Antonie G, Bjerve Kristian S, Hovdal Harald, Lilleås Finn, Midgard Rune, Pedersen Tom, Šaltytė Benth Jūratė, Torkildsen Øivind, Wergeland Stig, Michelsen Annika E, Aukrust Pål, Ueland Thor, Holmøy Trygve
Department of Neurology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway; KG Jebsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
J Neuroimmunol. 2015 Mar 15;280:21-8. doi: 10.1016/j.jneuroim.2015.02.001. Epub 2015 Feb 11.
To explore if vitamin D modulates interferon-β1a treatment effects in relapsing-remitting multiple sclerosis, we examined relationships between serum vitamin D and magnetic resonance imaging (MRI) activity and ten systemic inflammation markers in 88 patients, before and during treatment. Odds ratios for all MRI parameters were negatively associated with vitamin D levels before therapy, but converged to equally low values irrespective of vitamin D status during treatment. During therapy, similar alterations of MRI activity and inflammation markers were found across patients categorized by mean vitamin D values. This suggests that vitamin D status has no major influence on interferon-β1a treatment effects.
为了探究维生素D是否会调节复发缓解型多发性硬化症患者中干扰素β-1a的治疗效果，我们在88例患者治疗前及治疗期间，检测了血清维生素D水平与磁共振成像（MRI）活性以及十种全身炎症标志物之间的关系。所有MRI参数的比值比在治疗前与维生素D水平呈负相关，但在治疗期间，无论维生素D状态如何，这些比值比均趋于同样低的值。在治疗期间，按平均维生素D值分类的患者中，MRI活性和炎症标志物出现了相似的变化。这表明维生素D状态对干扰素β-1a的治疗效果没有重大影响。
